Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in Japanese ALK+ NSCLC (J-ALTA)
NCT03410108Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Started Jan 2018; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03410108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410108.